Tri-vylibra Lo Kit
Product Images NDC 50102-231

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tri-vylibra Lo (NDC 50102-231). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Afaxys Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Blister Pack Label (Norgestimate Fig1)

An illustrated medication schedule for Tri-VyLibra Lo, showing a weekly dose calendar with circles representing daily tablets. Each week is color-coded: week 1 is white to off-white, week 2 pale blue to bluish white, week 3 blue to light blue, and week 4 green. The active ingredients, norgestimate and ethinyl estradiol, with tablet strengths for week 3, are noted below the schedule.*

FDA Label Image

Day Label Sticker (Norgestimate Fig2)

An instructional diagram for the Tri-VyLibra Lo kit showing how to apply the correct day label (MON to SUN) on a pill card. It illustrates placing the label above the tablet slots, which are color-coded in rows by week and shade from white to green, representing different tablet types in the kit. The image includes a hand positioning the day label on the pack.*

FDA Label Image

Pregnancy Chart (Norgestimate Fig3)

A forest plot chart illustrating effect estimates with odds ratios (OR) and relative risks (RR) from multiple women's health studies conducted between 2002 and 2017. The chart compares ever use and current use across different cohorts, showing point estimates with confidence intervals along a horizontal axis from -1.5 to 2.*

FDA Label Image

Blister Pack Label1 (Norgestimate Fig4)

An illustration depicting a vertical scale of pregnancy rates per 100 women per year, ranging from fewer than 1 to 85 or more pregnancies. It categorizes birth control methods by effectiveness, listing implants, injections, intrauterine devices, and sterilization as most effective with fewer pregnancies, followed by birth control pills, skin patch, and vaginal ring with hormones, then condoms and diaphragm, then no sex during fertile days, spermicide, and withdrawal, and finally no birth control leading to the most pregnancies.*

FDA Label Image

Day Label Sticker1 (Norgestimate Fig5)

An illustrated pill calendar for the Tri-VyLibra Lo kit showing 28 circular pill slots arranged in four horizontal rows labeled Week 1 to Week 4 and days of the week above. Pills are color-coded with white to off white for Week 1, pale blue to bluish white for Week 2, blue to light blue for Week 3 with dosage details of norgestimate and ethinyl estradiol tablets, and green for Week 4.*

FDA Label Image

Package Label-principal Display Panel- Carton Label (Norgestimate Fig6)

Illustration shows how to use the day label strip with the Tri-VyLibra Lo kit of norgestimate and ethinyl estradiol tablets. It depicts the weekly pill pack with rows labeled by week and color-coded pills varying from white to green. An instruction indicates peeling and placing the correct day label starting from Sunday.*

FDA Label Image

Norgestimate Fig7

Tri-VyLibra Lo Kit containing Norgestimate and Ethinyl Estradiol tablets with varying dosages of 0.180 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.250 mg/0.025 mg. The packaging states a 28-day regimen with 28 tablets per blister pack. Labeler is Afaxys Pharma, LLC, Charleston, SC, and manufacturer is Aurobindo Pharma Limited, India. The label includes usage warnings and the NDC 50102-231-11.*

FDA Label Image

Chemical Structure (Norgestimate Str)

Chemical structure diagram showing the active ingredients of Tri-VyLibra Lo: Norgestimate on the left and Ethinyl Estradiol on the right, each labeled with their respective names below the structures.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.